| Adriana M Fitzsimmons, MD | |
|
3535 Route 66, Parkway 100, Neptune, NJ 07753-2625 | |
| (733) 264-3435 | |
| (732) 643-4398 |
| Full Name | Adriana M Fitzsimmons |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 26 Years |
| Location | 3535 Route 66, Neptune, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285606921 | NPI | - | NPPES |
| 8706603 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MA71513 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jersey Shore University Medical Center | Neptune, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hackensack Meridian Health Medical Group - Specialty Care Pc | 9133032519 | 1090 |
News Archive
After all standard treatments had failed, a new cancer treatment has stopped the growth of aggressive sarcomas in two recent patients. These results are similar to the new protocol's previous success against several cancers, including melanoma, pancreatic, colon, mesothelioma and other sarcomas.
A sugar-loving protein drives the growth of Kaposi sarcoma (KS) tumors, according to a study published on October 1st in The Journal of Experimental Medicine. Interfering with these sugary interactions inhibited growth of Kaposi sarcomas in mice, hinting at the potential for new treatment strategies in humans.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Officials in Oregon say hospitals accidentally killed 32 patients; in Texas, as the immigration debate simmers, the government is tallying illegal immigrants' health costs.
› Verified 3 days ago
| Entity Name | Hackensack Meridian Health Medical Group - Specialty Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215989249 PECOS PAC ID: 9133032519 Enrollment ID: O20031111000524 |
News Archive
After all standard treatments had failed, a new cancer treatment has stopped the growth of aggressive sarcomas in two recent patients. These results are similar to the new protocol's previous success against several cancers, including melanoma, pancreatic, colon, mesothelioma and other sarcomas.
A sugar-loving protein drives the growth of Kaposi sarcoma (KS) tumors, according to a study published on October 1st in The Journal of Experimental Medicine. Interfering with these sugary interactions inhibited growth of Kaposi sarcomas in mice, hinting at the potential for new treatment strategies in humans.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Officials in Oregon say hospitals accidentally killed 32 patients; in Texas, as the immigration debate simmers, the government is tallying illegal immigrants' health costs.
› Verified 3 days ago
| Entity Name | Hmh Hospitals Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679680243 PECOS PAC ID: 4587572870 Enrollment ID: O20060103000485 |
News Archive
After all standard treatments had failed, a new cancer treatment has stopped the growth of aggressive sarcomas in two recent patients. These results are similar to the new protocol's previous success against several cancers, including melanoma, pancreatic, colon, mesothelioma and other sarcomas.
A sugar-loving protein drives the growth of Kaposi sarcoma (KS) tumors, according to a study published on October 1st in The Journal of Experimental Medicine. Interfering with these sugary interactions inhibited growth of Kaposi sarcomas in mice, hinting at the potential for new treatment strategies in humans.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Officials in Oregon say hospitals accidentally killed 32 patients; in Texas, as the immigration debate simmers, the government is tallying illegal immigrants' health costs.
› Verified 3 days ago
| Entity Name | Hackensack Meridian Health Medical Group - Complex Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154379626 PECOS PAC ID: 0446272298 Enrollment ID: O20060109000000 |
News Archive
After all standard treatments had failed, a new cancer treatment has stopped the growth of aggressive sarcomas in two recent patients. These results are similar to the new protocol's previous success against several cancers, including melanoma, pancreatic, colon, mesothelioma and other sarcomas.
A sugar-loving protein drives the growth of Kaposi sarcoma (KS) tumors, according to a study published on October 1st in The Journal of Experimental Medicine. Interfering with these sugary interactions inhibited growth of Kaposi sarcomas in mice, hinting at the potential for new treatment strategies in humans.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Officials in Oregon say hospitals accidentally killed 32 patients; in Texas, as the immigration debate simmers, the government is tallying illegal immigrants' health costs.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adriana M Fitzsimmons, MD 3535 Route 66, Parkway 100, Neptune, NJ 07753-2625 Ph: (732) 643-4350 | Adriana M Fitzsimmons, MD 3535 Route 66, Parkway 100, Neptune, NJ 07753-2625 Ph: (733) 264-3435 |
News Archive
After all standard treatments had failed, a new cancer treatment has stopped the growth of aggressive sarcomas in two recent patients. These results are similar to the new protocol's previous success against several cancers, including melanoma, pancreatic, colon, mesothelioma and other sarcomas.
A sugar-loving protein drives the growth of Kaposi sarcoma (KS) tumors, according to a study published on October 1st in The Journal of Experimental Medicine. Interfering with these sugary interactions inhibited growth of Kaposi sarcomas in mice, hinting at the potential for new treatment strategies in humans.
Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.
Officials in Oregon say hospitals accidentally killed 32 patients; in Texas, as the immigration debate simmers, the government is tallying illegal immigrants' health costs.
› Verified 3 days ago
Nastacia Chavannes, M.D Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: Jersey Shore University Medical Center, 1943 Route 33, Neptune, NJ 07753 Phone: 732-755-5500 | |
Mrs. Nicole Elizabeth Smith, APN Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1945 Nj-33, Jsumc-inpatient Wound Care, Neptune, NJ 07753 Phone: 732-776-4680 Fax: 732-776-4337 | |
Dr. Tony Issac, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1945 State Route 33, Neptune, NJ 07753 Phone: 732-776-4930 Fax: 732-776-4929 | |
David B Duncan, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1945 Route 33, 1st Floor Amdur Pavillion, Neptune, NJ 07753 Phone: 732-897-3620 Fax: 732-897-3619 | |
Melissa Calt, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1945 State Route 33, Neptune, NJ 07753 Phone: 732-776-4483 Fax: 732-776-4798 | |
Dr. Andrew Manoski, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1945 Route 33, Neptune, NJ 07753 Phone: 732-643-4363 Fax: 732-643-4376 | |
Dr. Huma Baqui, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1944 Corlies Avenue, Suite 206, Neptune, NJ 07753 Phone: 732-774-8282 |